Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-23-149281
Filing Date
2023-05-19
Accepted
2023-05-19 16:01:11
Documents
19
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d506208d10ka.htm   iXBRL 10-K/A 76335
2 EX-23.1 d506208dex231.htm EX-23.1 5796
3 EX-31.3 d506208dex313.htm EX-31.3 5763
4 EX-31.4 d506208dex314.htm EX-31.4 4027
5 EX-32.3 d506208dex323.htm EX-32.3 4542
6 EX-32.4 d506208dex324.htm EX-32.4 4472
  Complete submission text file 0001193125-23-149281.txt   334032

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA aryb-20221231.xsd EX-101.SCH 4931
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE aryb-20221231_cal.xml EX-101.CAL 641
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aryb-20221231_def.xml EX-101.DEF 18567
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE aryb-20221231_lab.xml EX-101.LAB 24882
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aryb-20221231_pre.xml EX-101.PRE 19844
13 EXTRACTED XBRL INSTANCE DOCUMENT d506208d10ka_htm.xml XML 8906
Mailing Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141
Business Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Filer) CIK: 0001805387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39311 | Film No.: 23939885
SIC: 2834 Pharmaceutical Preparations